Analyst Group publicerade idag en analys av Aptahem med titeln ”I väntan på återupptagen studie” som kan läsas på Analyst Groups webbsida och på www.aptahem.com. För ytterligare information: Aptahem AB Mikael Lindstam, VD Tel: 0766-33 36 99 Epost: ml@aptahem.com...
Read MoreAptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed at the physical event in Stockholm on 20 September at 15.00 CET. More...
Read MoreBioStock published an article on 5 September 2023 about Aptahem, which can be read in full below. For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently...
Read MoreSammanfattning av delårsrapport Andra kvartalet (2023-04-01 – 2023-06-30) Rörelsens intäkter uppgick till 411 (1 127) KSEK Resultat efter finansiella poster -2 736 (-1 793) KSEK Resultat per aktie -0,02 (-0,01) SEK Likvida medel uppgick per 2023-06-30 till 5 782...
Read MoreBioStock published an article on 24 July 2023 about Aptahem, which can be read in full below. Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study...
Read MoreAptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that in the double-blinded randomized placebo controlled first-in-human (FIH) clinical trial further analytic studies on the mechanism of Apta-1...
Read MoreEJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Read MoreEJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
Read MoreBioStock published an article on 27 June 2023 about Aptahem, which can be read in full below. Sepsis affects millions of people globally every year and results in significant morbidity and mortality. The standard treatment consists mainly of antibiotics,...
Read MoreAptahem participates in the conference International Society on Thrombosis and Haemostasis (ISTH) on 24-28 June where CSO Dr Luiza Jedlina has presented a poster. The poster, entitled “The RNA aptamer, Apta-1 targeting evolutionarily conserved motif on thrombin cures endotoxemia...
Read More